This result suggests that the μPL-based system helped ameliorate the dysbindin-induced cognitive deficits similarly to the free drug, with one single injection of particles releasing a lower amount of drug than the conventional dose. The gene discussed is DTNBP1; the disease is Cognitive impairment.